In addition, these contracts have facilitated the filing of applications for authorisation, patents and other intellectual property applications by non-European auditors who request an evaluation of their products under these contracts. This program has also been used by the DMID mission to support research initiated by researchers by providing critical data needed to apply for grants or other funding. These contracts have also enabled product promoters and sponsors to make important decisions for the drugs of candidate therapists, vaccines and diagnostic devices. RHB-107 was selected by NIAID for in vitro testing after analyzing NIAID data on the potential mechanism of action of the drug and potential activity against SARS-CoV-2. In the future, the “Preclinical Models of Infectious Diseases” program will include non-traditional animal models and models that may replace animals in product screening and efficacy studies. The program will continue to provide the ability and ability to design and use animal and animal substitution models (e.g. B smart organ technology) of infectious diseases for the evaluation of dassieb and products, and will address a critical phase of this pipeline by allowing to fill in vitro tests and possible clinical evaluations. “RHB-107 is the second trial drug redHill is evaluating for COVID-19, underscoring our commitment to global efforts to develop treatment for patients with this disease,” said Terry F. Plasse MD, RedHill Medical Director. This new agreement will facilitate the preclinical assessment of RHB-107 as a COVID 19 POTENTIAL treatment. TEL-AVIV, Israel and RALEIGH, N.C., April 20, 2020 (GLOBE NEWSWIRE) — RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “company”), a biopharmaceutical company, announced today that it has reached an agreement with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to test its test drug RHB-107 (upamostat , WX-671) 1 to test activity against SARS-COV-2 , the virus responsible for coronavirus disease (COVID-19).

RHB-107 (upamostat) RHB-107 is a powerful, first-class, first-class, oral-administered inhibitor of several serine proteases that target cancer, inflammatory lung disease and gastrointestinal diseases. RHB-107 was conducted in several Phase 1 studies and two proof-of-concept Phase 2 studies that demonstrated its clinical tolerance profile in more than 300 patients. RedHill has acquired the worldwide exclusivity of RHB-107, with the exception of China, Hong Kong, Taiwan and Macau, germany`s Heidelberg Pharmaceuticals (formerly WILEX AG) for all indications. The appeal is still in the preliminary phase, with the formal request for proposals (RFP) expected by 13 May 2016. This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995.